GPT and metabolic syndrome: The present prospective study confirmed the effectiveness of 48‐week pemafibrate treatment in 91 patients with MASLD complicated dyslipidemia: pemafibrate improved liver enzyme levels (ALT, γ‐GTP, and ALP) and lipid metabolism, without changes in body weight/BMI between the first 12 and 48 weeks of treatment.